- Home
- MCN vs MRSN Comparison
MCN vs MRSN Comparison
Compare MCN & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCN | MRSN |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 138.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | MCN | MRSN |
|---|---|---|
| Price | $6.11 | $29.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.38 |
| AVG Volume (30 Days) | 52.9K | ★ 114.7K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 9.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.69 | $5.21 |
| 52 Week High | $8.60 | $36.25 |
Technical Indicators
Market Signals| Indicator | MCN | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 68.49 | 78.89 |
| Support Level | $5.88 | $28.11 |
| Resistance Level | $6.12 | $29.15 |
| Average True Range (ATR) | 0.06 | 0.57 |
| MACD | 0.02 | -0.47 |
| Stochastic Oscillator | 96.67 | 48.68 |
Price Performance
Historical ComparisonAbout MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.